Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers
Based on this point that some of the cancers do not appropriately respond to conventional therapy and there is the possibility of relapse, immunotherapy is currently under investigation. Cancer immunotherapies are widely recognized as transformational for several cancers and enable to move to the fr...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2021-11-01
|
| Series: | Acta Medica Iranica |
| Subjects: | |
| Online Access: | https://acta.tums.ac.ir/index.php/acta/article/view/8731 |
| _version_ | 1818997384892383232 |
|---|---|
| author | Mehran Bahraini Alieh Fazeli |
| author_facet | Mehran Bahraini Alieh Fazeli |
| author_sort | Mehran Bahraini |
| collection | DOAJ |
| description | Based on this point that some of the cancers do not appropriately respond to conventional therapy and there is the possibility of relapse, immunotherapy is currently under investigation. Cancer immunotherapies are widely recognized as transformational for several cancers and enable to move to the front-line therapy with few side effects. One of its new branches is treatment with T-cells that have been changed their receptor. The research on these cells is generally according to the design of a receptor against a specific tumor antigen. Also, manipulation of regulatory T-cell (Tregs), as the barriers to useful immune responses in the tumor microenvironment, will promote Tregs -targeted therapeutic opportunities and improve the efficacy of the current cancer treatment, such as radiation and chemotherapy. This review attempts to show novel insights into the roles of Tregs in cancer which can be considered as a promising anticancer therapeutic strategy for targeting them and approaches for generation of tumor antigen-specific T lymphocytes (AST) using chimeric antigen receptors. |
| first_indexed | 2024-12-20T21:44:47Z |
| format | Article |
| id | doaj.art-6dcd93027cb0443fad7ae673b4e7770f |
| institution | Directory Open Access Journal |
| issn | 0044-6025 1735-9694 |
| language | English |
| last_indexed | 2024-12-20T21:44:47Z |
| publishDate | 2021-11-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | Acta Medica Iranica |
| spelling | doaj.art-6dcd93027cb0443fad7ae673b4e7770f2022-12-21T19:25:42ZengTehran University of Medical SciencesActa Medica Iranica0044-60251735-96942021-11-0157057710.18502/acta.v59i10.77608731Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancersMehran BahrainiAlieh FazeliBased on this point that some of the cancers do not appropriately respond to conventional therapy and there is the possibility of relapse, immunotherapy is currently under investigation. Cancer immunotherapies are widely recognized as transformational for several cancers and enable to move to the front-line therapy with few side effects. One of its new branches is treatment with T-cells that have been changed their receptor. The research on these cells is generally according to the design of a receptor against a specific tumor antigen. Also, manipulation of regulatory T-cell (Tregs), as the barriers to useful immune responses in the tumor microenvironment, will promote Tregs -targeted therapeutic opportunities and improve the efficacy of the current cancer treatment, such as radiation and chemotherapy. This review attempts to show novel insights into the roles of Tregs in cancer which can be considered as a promising anticancer therapeutic strategy for targeting them and approaches for generation of tumor antigen-specific T lymphocytes (AST) using chimeric antigen receptors.https://acta.tums.ac.ir/index.php/acta/article/view/8731tumor microenvironmentchimeric t cell receptorsregulatory t-lymphocytesadoptive immunotherapy |
| spellingShingle | Mehran Bahraini Alieh Fazeli Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers Acta Medica Iranica tumor microenvironment chimeric t cell receptors regulatory t-lymphocytes adoptive immunotherapy |
| title | Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers |
| title_full | Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers |
| title_fullStr | Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers |
| title_full_unstemmed | Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers |
| title_short | Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers |
| title_sort | adoptive chimeric antigen receptor t cell car t and treg cell based immunotherapies frontier therapeutic aspects in cancers |
| topic | tumor microenvironment chimeric t cell receptors regulatory t-lymphocytes adoptive immunotherapy |
| url | https://acta.tums.ac.ir/index.php/acta/article/view/8731 |
| work_keys_str_mv | AT mehranbahraini adoptivechimericantigenreceptortcellcartandtregcellbasedimmunotherapiesfrontiertherapeuticaspectsincancers AT aliehfazeli adoptivechimericantigenreceptortcellcartandtregcellbasedimmunotherapiesfrontiertherapeuticaspectsincancers |